Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovaBridge BiosciencesNBP · Entity 6324 | Chief Medical Officer | September 17, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovaBridge Biosciences
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 181,636 |
Reported balance
After 2026-09-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-17 · Exercise / conversion · Acquired 23,695 · Balance 181,636 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2: Reported securities are represented by 10,302 ADSs. F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4: Reported securities are represented by 78,972 ADSs. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 173,427 |
Reported balance
After 2026-09-18 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-18 · Sale · Disposed 8,209 · Balance 173,427 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F5: Reported securities are represented by 3,569 ADSs. F6: Reported sales price represents the converted sales price of the ADSs of $1.6247. F7: Reported securities are represented by 75,403 ADSs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 72,120 |
Reported balance
After 2026-09-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-17 · Exercise / conversion · Disposed 10,302 · Balance 72,120 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F8: Reported securities represent ADSs. F9: On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2: Reported securities are represented by 10,302 ADSs.
F3: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
F4: Reported securities are represented by 78,972 ADSs.
F5: Reported securities are represented by 3,569 ADSs.
F6: Reported sales price represents the converted sales price of the ADSs of $1.6247.
F7: Reported securities are represented by 75,403 ADSs.
F8: Reported securities represent ADSs.
F9: On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 21, 2026 20:05 UTC | NovaBridge Biosciences NBP · Entity 6324 | SaleOrdinary Shares | 8,209 | $0.71 | $5,828.39 |
DisclosureSEC source: 0002089237-26-000008 · form4-09212026_040901.xml · nonDerivative · entry 2 Dennis Phillip Andrew · CIK 0002089237 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,427 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F5 · shares: Reported securities are represented by 3,569 ADSs. F6 · price: Reported sales price represents the converted sales price of the ADSs of $1.6247. F7 · balance_after: Reported securities are represented by 75,403 ADSs. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionRestricted Share Units · Derivative | 10,302 | $0.00 | $0.00 |
DisclosureSEC source: 0002089237-26-000008 · form4-09212026_040901.xml · derivative · entry 3 Dennis Phillip Andrew · CIK 0002089237 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,120 Underlying: Ordinary Shares · 10,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F8 · shares: Reported securities represent ADSs. F9 · derivative.exercise_date: On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month. F9 · derivative.expiration_date: On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F8 · derivative.underlying_shares: Reported securities represent ADSs. F8 · balance_after: Reported securities represent ADSs. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 20:05 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionOrdinary Shares | 23,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002089237-26-000008 · form4-09212026_040901.xml · nonDerivative · entry 1 Dennis Phillip Andrew · CIK 0002089237 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · shares: Reported securities are represented by 10,302 ADSs. F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4 · balance_after: Reported securities are represented by 78,972 ADSs. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 21:23 UTC | NovaBridge Biosciences NBP · Entity 6324 | SaleOrdinary Shares | 8,494 | $0.66 | $5,606.04 |
DisclosureSEC source: 0002089237-26-000006 · form4-06222026_090646.xml · nonDerivative · entry 2 Dennis Phillip Andrew · CIK 0002089237 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,941 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F5 · shares: Reported securities are represented by 3,693 ADSs. F6 · price: Reported sales price represents the converted sales price of the ADSs of $1.51. F7 · balance_after: Reported securities are represented by 68,670 ADSs. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:23 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionRestricted Share Units · Derivative | 10,302 | $0.00 | $0.00 |
DisclosureSEC source: 0002089237-26-000006 · form4-06222026_090646.xml · derivative · entry 3 Dennis Phillip Andrew · CIK 0002089237 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,422 Underlying: Ordinary Shares · 10,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F8 · shares: Reported securities represent ADSs. F9 · derivative.exercise_date: On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month. F9 · derivative.expiration_date: On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F8 · derivative.underlying_shares: Reported securities represent ADSs. F8 · balance_after: Reported securities represent ADSs. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:23 UTC | NovaBridge Biosciences NBP · Entity 6324 | Exercise / conversionOrdinary Shares | 23,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002089237-26-000006 · form4-06222026_090646.xml · nonDerivative · entry 1 Dennis Phillip Andrew · CIK 0002089237 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · shares: Reported securities are represented by 10,302 ADSs. F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. F4 · balance_after: Reported securities are represented by 72,363 ADSs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.